CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV.
CD1d and CD1d-restricted natural killer T (NKT) cells serve as a natural bridge between innate and adaptive immune responses to microbes. CD1d downregulation is utilized by a variety of microbes to evade immune detection. We demonstrate here that CD1d is downregulated in human papillomavirus (HPV)-positive cells in vivo and in vitro. CD1d immunoreactivity was strong in HPV-negative normal cervical epithelium but absent in HPV16-positive CIN1 and HPV6-positive condyloma lesions. We used two cell lines for in vitro assay; one was stably CD1d-transfected cells established from an HPV-negative cervical cancer cell line, C33A (C33A/CD1d), and the other was normal human vaginal keratinocyte bearing endogenous CD1d (Vag). Flow cytometry revealed that cell surface CD1d was downregulated in both C33A/CD1d and Vag cells stably transfected with HPV6 E5 and HPV16 E5. Although the steady-state levels of CD1d protein decreased in both E5-expressing cell lines compared to empty retrovirus-infected cells, CD1d mRNA levels were not affected. Confocal microscopy demonstrated that residual CD1d was not trafficked to the E5-expressing cell surface but colocalized with E5 near the endoplasmic reticulum (ER). In the ER, E5 interacted with calnexin, an ER chaperone known to mediate folding of CD1d. CD1d protein levels were rescued by the proteasome inhibitor, MG132, indicating a role for proteasome-mediated degradation in HPV-associated CD1d downregulation. Taken together, our data suggest that E5 targets CD1d to the cytosolic proteolytic pathway by inhibiting calnexin-related CD1d trafficking. Finally, CD1d-mediated production of interleukin-12 from the C33A/CD1d cells was abrogated in both E5-expressing cell lines. Decreased CD1d expression in the presence of HPV E5 may help HPV-infected cells evade protective immunological surveillance.
Miura
Shiho
S
Department of Obstetrics and Gynecology, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan.
Kawana
Kei
K
Schust
Danny J
DJ
Fujii
Tomoyuki
T
Yokoyama
Terufumi
T
Iwasawa
Yuki
Y
Nagamatsu
Takeshi
T
Adachi
Katsuyuki
K
Tomio
Ayako
A
Tomio
Kensuke
K
Kojima
Satoko
S
Yasugi
Toshiharu
T
Kozuma
Shiro
S
Taketani
Yuji
Y
D056704:Adaptive Immunity; D052685:Alphapapillomavirus / Q000235:genetics / Q000276:immunology*; D055610:Antigens, CD1d / Q000276:immunology*; D045744:Cell Line, Tumor; D015536:Down-Regulation; D005260:Female; D006801:Humans; D057131:Immune Evasion; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology* / Q000821:virology; D000086082:Viroporin Proteins
D055610:Antigens, CD1d; D009856:Oncogene Proteins, Viral; C526877:CD1D protein, human; C083104:E5 protein, Human papillomavirus type 6; C054859:oncogene protein E5, Human papillomavirus type 16; D000086082:Viroporin Proteins
Immunology. 1993 Dec;80(4):561-5
7508419
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13938-43
10570177
J Virol. 1993 Oct;67(10):6170-8
7690419
Nat Immunol. 2006 Aug;7(8):835-42
16845396
Curr Top Microbiol Immunol. 2007;314:215-50
17593663
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11811-6
16091469
Virus Res. 2002 Sep;88(1-2):103-17
12297330
Virology. 2009 Feb 20;384(2):410-4
18986661
N Engl J Med. 1998 Feb 12;338(7):423-8
9459645
Virology. 2005 Jul 5;337(2):242-52
15916790
J Immunol. 2005 Sep 1;175(5):3197-206
16116210
Nat Immunol. 2003 Dec;4(12):1230-7
14578883
J Immunol. 2000 Oct 1;165(7):4076-85
11034419
J Virol. 1995 May;69(5):3185-92
7707548
Infect Immun. 2008 Jul;76(7):3011-8
18458073
Nat Rev Immunol. 2003 Feb;3(2):133-46
12563297
Hum Pathol. 1992 Feb;23(2):117-28
1310950
Annu Rev Immunol. 2004;22:817-90
15032598
J Cell Biol. 2000 Jan 24;148(2):305-15
10648563
J Med Microbiol. 2006 Sep;55(Pt 9):1175-1185
16914646
J Immunol. 1991 Oct 15;147(8):2518-24
1717564
Virus Res. 2006 Feb;115(2):158-68
16168512
Biol Reprod. 1999 Feb;60(2):508-14
9916021
Oncogene. 2002 Nov 7;21(51):7808-16
12420217
J Immunol. 2002 Mar 1;168(5):2424-32
11859134
J Biol Chem. 2007 Mar 9;282(10):7368-75
17215251
J Gen Virol. 2004 Oct;85(Pt 10):2809-2814
15448341
Oncogene. 2003 Aug 11;22(33):5201-7
12910257
J Biol Chem. 2002 Nov 22;277(47):44838-44
12239218
J Biol Chem. 1999 Apr 2;274(14):9289-95
10092605
Nature. 2005 Mar 24;434(7032):525-9
15791258
Semin Immunol. 2000 Dec;12(6):543-50
11145860
Virol J. 2007 Oct 30;4:116
17971213
Int J Cancer. 2005 Jan 10;113(2):276-83
15386416
Int J Cancer. 2006 Nov 1;119(9):2105-12
16823848
Infect Immun. 2003 Oct;71(10):5447-55
14500461
Immunity. 2000 Feb;12(2):211-21
10714687
J Clin Invest. 2005 May;115(5):1369-78
15864354
J Clin Microbiol. 2000 Jan;38(1):357-61
10618116
Nat Rev Cancer. 2002 May;2(5):342-50
12044010
Oncogene. 2002 Jan 10;21(2):248-59
11803468
J Immunol. 2005 Sep 15;175(6):3584-93
16148102
Science. 1994 Jul 8;265(5169):259-62
7517575
J Immunol. 2004 Apr 15;172(8):4667-71
15067039